ArticleCell reports. Medicine2023
ZNF671 methylation test in cervical scrapings for cervical intraepithelial neoplasia grade 3 and cervical cancer detection.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Analysis of DNA methylation markers for diagnosing cervical precancer and cancer: A single-center cross-sectional study.Oncology letters · 2026Article
- SOX1/PAX1 Methylation for Triage of HPV-Positive Women in Cervical Cancer Screening: A Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- PAX1 methylation for triage of HR-HPV-positive women: a comparative analysis with cytology and HPV16/18 genotyping.BMC cancer · 2026Article
- Article
- Pan-cancer differentially methylated regions are promising biomarkers for non-invasive diagnosis in multiple cancers.iScience · 2026Article
- Advances in the application of gene methylation detection in cervical cancer screening.Frontiers in oncology · 2026Review
- A Holistic Framework for Cervical Cancer Screening and Risk Stratification: Integrating Etiology, Morphology, Epigenetics, and Microecology.Cancer management and research · 2026Review
- Diagnostic Accuracy of DNA Methylation Markers for Detecting Cervical Precancer and Cervical Cancer: A Systematic Review and Meta-analysis.Archives of academic emergency medicine · 2026Review
- DNA Methylation in Cervical Intraepithelial Neoplasia and Cervical Cancer: Triage and Management.Current topics in microbiology and immunology · 2026Review
- Comparative performance of hrHPV testing and PAX1/ZNF671 methylation in triaging women with abnormal cytology: a study of paired urine, vaginal and cervical scrape samples.Frontiers in oncology · 2026Article
- Application of a modified MSRE-qPCR method for detecting circulating cell-free DNA methylation in cervical cancer.Frontiers in oncology · 2026Article
- Prospective Study on Clinical Performance of Host DNA Methylation Assay for Triage in Women Who Are HPV-Positive - 4 Provinces, China, 2018-2021.China CDC weekly · 2025Article
- The DNA Methylation MarkerCancers · 2025Article
- Article
- Intervention of machine learning in bladder cancer research using multi-omics datasets: systematic review on biomarker identification.Discover oncology · 2025Review
- Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.Clinical epigenetics · 2025Review
- Article
- Comparative evaluation of two DNA methylation assays for triage of hrHPV E6/E7 mRNA-positive women.Frontiers in public health · 2025Article
- A Predictive Model Using Six Genes DNA Methylation Markers to Identify Individuals With High Risks of High-Grade Squamous Intraepithelial Lesions and Cervical Cancer.International journal of women's health · 2025Article
- Cervical cancer screening: efficacy of PAX1 and JAM3 methylation assay in the triage of atypical squamous cell of undetermined significance (ASC-US).BMC cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Peng ZhuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P.R. China.
Jing XiongDepartment of Gynaecology and Obstetrics, The Second Xiangya Hospital, Central South University, 139 Renming Road, Changsha 410011, P.R. China.
Ding YuanHealth Management Center, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, P.R. China.
Xiang LiDepartment of Gynaecology, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha 410013, P.R. China.
Lili LuoDepartment of Gynaecology, The First Affiliated Hospital of Shantou University Medical College, Shantou, P.R. China.
Ju HuangDepartment of Gynaecology, The First Affiliated Hospital of Shantou University Medical College, Shantou, P.R. China.
Binbin WangDepartment of Obstetrics and Gynecology, Loudi Central Hospital, 51 Chang Qing Road, Loudi 417000, P.R. China.
Quanfang NieDepartment of Obstetrics and Gynecology, Loudi Central Hospital, 51 Chang Qing Road, Loudi 417000, P.R. China.
Shuli WangDepartment of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, P.R. China.
Liying DangDepartment of Obstetrics and Gynecology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, P.R. China.
Yan ChenXiangya Medical Laboratory, Central South University, 110 Xiangya Road, Changsha 410078, P.R. China.
Shu LiXiangya Medical Laboratory, Central South University, 110 Xiangya Road, Changsha 410078, P.R. China.
Yuhang AnXiangya Medical Laboratory, Central South University, 110 Xiangya Road, Changsha 410078, P.R. China.
Li YangXiangya Medical Laboratory, Central South University, 110 Xiangya Road, Changsha 410078, P.R. China.
Rong LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P.R. China.
Yanping HeKey Specialty of Clinical Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, P.R. China.
Xiong LiKey Specialty of Clinical Pharmacy, The First Affiliated Hospital, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong, P.R. China.
Puxiang ChenDepartment of Gynaecology and Obstetrics, The Second Xiangya Hospital, Central South University, 139 Renming Road, Changsha 410011, P.R. China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P.R. China.
Qing LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, 110 Xiangya Road, Changsha 410078, P.R. China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P.R. China. Electronic address: liqing9251026@csu.edu.cn.
Central South University · CNLoudi Central Hospital · CNShantou University · CNZhengzhou Central Hospital · CNGuangdong Pharmaceutical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective triage of high-risk human papillomavirus (hrHPV)+ women is warranted to avoid unnecessary referral and overtreatment. Molecular triage tests have recently begun to impact cervical intraepithelial neoplasia grade 3 (CIN3) or cervical cancer (CC), termed CIN3+, detection. We find that zinc finger protein 671 methylation (ZNF671
Indexed as
Uterine Cervical DysplasiaUterine Cervical NeoplasmsDNA MethylationFemaleHuman papillomavirus 16Human papillomavirus 18HumansTumor Suppressor ProteinsTumor Suppressor ProteinsZNF671 protein, humanASCUScervical cancerCIN3+ detectionDNA methylationhrHPVThinprep cytologic testZNF671
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.